Bristol Will Use Yervoy’s Successful Launch As Model For Opdivo
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma posted strong results in the third quarter for its oncology franchise, but looks to its future in cancer immunotherapy to bring about growth post-patent losses.